# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects

> **NCT05308940** · PHASE1 · COMPLETED · sponsor: **Shenzhen Turier Biotech Co., Ltd** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TB001
- **DRUG:** TB001
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05308940
- **Lead sponsor:** Shenzhen Turier Biotech Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308940, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05308940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*